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Edited by Veli-Pekka LehtoAbstract F2L, a peptide derived from heme-binding protein,
was originally identiﬁed as an endogenous ligand for formyl pep-
tide receptor-like (FPRL)2. Previously, we reported that F2L
inhibits FPR and FPRL1-mediated signaling in neutrophils.
Since endothelial cells express functional FPRL1, we examined
the eﬀect of F2L on LL-37 (an FPRL1 agonist)-induced signal-
ing in human umbilical vein endothelial cells (HUVECs). F2L
stimulated the chemotactic migration in HUVECs. However,
F2L inhibited FPRL1 activity, resulting in the inhibition of cell
proliferation and tube formation induced by LL-37 in HUVECs.
We suggest that F2L will potentially be useful in the study of
FPRL1 signaling and the development of drugs to treat diseases
involving the FPRL1 in the vascular system.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Angiogenesis is a crucial step in the physiological and path-
ological processes, which include normal embryonic develop-
ment, wound healing, inﬂammation, and the metastasis of
malignant tumors [1]. Previous studies have shown that vari-
ous cytokines, including vascular endothelial growth factor,
tumor necrosis factor-a, and several chemokines increase che-Abbreviations: FPR, formyl peptide receptor; FPRL, FPR-like; PTX,
pertussis toxin; WKYMVm, Trp-Lys-Tyr-Met-Val-D-Met; F2L, Ac-
MLGMIKNSLFGSVETWPWQVL; HUVECs, human umbilical vein
endothelial cells; EBM, endothelial basal medium; WRW4,
WRWWWW; FBS, fetal bovine serum; S1P, Sphingosine 1-phosphate;
HPF, high power ﬁelds
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doi:10.1016/j.febslet.2007.12.015motactic migration as well as the stimulation of angiogenic
activity in endothelial cells [2–4]. Bioactive lipid molecule,
sphingosine 1-phosphate (S1P), has also been reported to mod-
ulate some physiological activities in endothelial cells [5–7].
S1P induces chemotactic migration and angiogenesis in human
umbilical vein endothelial cells (HUVECs) [5–7]. Since the
activity of endothelial cells is vital for the regulation of several
vascular biological events which result in angiogenesis and vas-
cular inﬂammation, the identiﬁcation of molecules inhibiting
endothelial cell-mediated signaling will consequently be very
important for the treatment of vascular diseases.
The formyl peptide receptor (FPR) family is a class of char-
acteristic chemoattractant receptors, which are highly ex-
pressed in phagocytic cells such as neutrophils, monocytes,
and dendritic cells [8–10]. In addition, the FPR, FPR-like
(FPRL)1, and FPRL2 are three members of the FPR family
which have been reported in humans [8–10]. The activation
of a member of the FPR family mediates the chemotactic
migration of phagocytes. On the signaling mechanism involved
in FPR family-mediated chemotactic migration, pertussis toxin
(PTX)-sensitive Gi-protein(s)-mediated signaling has been
known to play a key role. Chemotactic migration of human
monocytes or neutrophils by FPR family agonists including
serum amyloid A and His-Arg-Tyr-Leu-Phe-Met was com-
pletely inhibited by PTX [11,12]. Furthermore, this indicates
that these receptors are coupled with the Gi subfamily of G
proteins [8–10], and consequently play an important functional
role in the regulation of defense activities against pathogen
infection by modulating the activities of phagocytes. These
receptors were found to be involved in chemotaxis, superoxide
generation, and exocytosis in human neutrophils [8–10]. In
addition, FPRL1 (a member of the FPR family) is also ex-
pressed in human endothelial cells, and its speciﬁc agonists
[LL-37 and Trp-Lys-Tyr-Met-Val-D-Met (WKYMVm)] have
been reported to activate FPRL1 and inducing cell prolifera-
tion and angiogenesis [13].
Previous studies have reported various types of ligand
belonging to the FPR [8–10]. In particular, F2L (Ac-
MLGMIKNSLFGSVETWPWQVL) has been identiﬁed as an
endogenous FPRL2 ligand originating from the heme-bindingblished by Elsevier B.V. All rights reserved.
274 S.Y. Lee et al. / FEBS Letters 582 (2008) 273–278protein cleavage product [14]. F2L is also known as an agonist
for the low aﬃnity fMLF receptor, FPR2 [15]. We very re-
cently demonstrated that F2L stimulates the chemotactic
migration of human neutrophils via FPR and FPRL1; how-
ever, we also found that it blocks the calcium signaling and
superoxide generation induced by fMLF, MMK-1, or
WKYMVm in human neutrophils [16]. In this study, we inves-
tigated the eﬀect of F2L on HUVECs with respect to chemo-
tactic migration, proliferation, and tube formation.2. Materials and methods
2.1. Reagents
The HUVECs and endothelial basal medium (EBM) were purchased
from Cambrex Corp. (East Rutherford, NJ, USA). The acetylated F2L
[14], LL-37 [17], and WRWWWW (WRW4) [18] were synthesized from
Anygen Co. Ltd. (Gwang-ju, Korea) and exceeded 95% purity. In
addition, the RPMI 1640 medium and fetal bovine serum (FBS) were
obtained from the Invitrogen Corp. (Carlsbad, CA, USA). Moreover,
S1P was purchased from Avanti Polar Lipids Inc. (Alabaster, AL,
USA). Finally, the PTX was purchased from Calbiochem (San Diego,
CA, USA).
2.2. Cell cultures
The HUVECs were cultured on a 0.02% gelatin-coated (Sigma, St.
Louis, MO) 10-cm dish in EBM supplemented with 10% FBS, 0.2 ml
of hydrocortisone, 2 ml of recombinant human ﬁbroblast growth fac-
tor-B, 0.5 ml of recombinant human vascular endothelial growth fac-
tor, 0.5 ml of recombinant insulin-like growth factor-1, 0.5 ml of
ascorbic acid, 0.5 ml of recombinant human epidermal growth factor,
0.5 ml of gentamycin sulfate amphotericin-B, and 0.5 ml of heparin.
The HUVECs were used for experiments between passages 3 and 10.
2.3. Chemotaxis assay
Chemotaxis assays were performed using multiwell chambers (Neu-
roprobe Inc., Gaithersburg, MD) as described previously [19]. In brief,
we pre-coated the polycarbonate ﬁlters (8 lm pore size) with 20 lg/ml
of ﬁbronectin in a 0.25% acetic acid solution. In addition, a dry coated
ﬁlter was likely placed on a 96-well chamber containing diﬀerent con-
centrations of stimuli. The HUVECs were suspended in RPMI at a
concentration of 1 · 106 cells/ml. Furthermore, 25 ll of the cell suspen-
sion was placed onto the upper well of the chamber. After a 4 h incu-
bation period at 37 C, non-migrating cells were removed by scarping,
and cells that migrated across the ﬁlter were dehydrated, ﬁxed, and
stained with hematoxylin (Sigma). The stained cells were assigned to
three randomly selected high power ﬁelds (HPF, 400·), which were
then counted for each well.
2.4. Cell proliferation assay
Endothelial cell proliferation was determined by DNA synthesis. In
brief, HUVECs were seeded at a density of 2 · 104 cells/well in gelatin-
coated 24-well plates, followed by allowing for cell growth and then
permitted to attach overnight. The cells were washed twice with
EBM and incubated for 4 h in M199 containing 1% FBS. The cells
were stimulated with each peptide for 48 h and [3H]-thymidine
(1 lCi) was added to each well just prior to the ﬁnal 12 h of incubation
[20].
2.5. Tube formation assay
Tube formation activity of the HUVECs was measured as previously
described [21]. Brieﬂy, 48-well culture plates were coated with Matrigel
(BD Biosciences, Franklin Lakes, NJ, USA) according to the manufac-
turers instructions. HUVECs were seeded on a layer of previously
polymerized Matrigel with each stimulus. After 18 h of incubation,
the cell morphology was visualized via phase-contrast microscopy
and photographed. The degree of tube formation was quantiﬁed by
measuring the length of tubes in three randomly chosen low-power
ﬁelds (50·) from each well, using the image-Pro Plus v4.5 (Media
Cybernetics, San Diego, CA).2.6. Statistical analysis
The results are expressed as the means ± S.E. of the number of deter-
minations indicated. The statistical tests used to assess the diﬀerences
were determined by a Students t-test. Statistical signiﬁcance was set
at a P-value <0.05.3. Results
3.1. F2L stimulates chemotactic migration in HUVECs
Since chemotactic migration is a representative function of
endothelial cells, we examined the eﬀect of F2L on the HU-
VEC chemotaxis. When we stimulated HUVECs with several
concentrations of F2L, we observed that F2L induced the che-
motactic migration of HUVECs in a concentration-dependent
manner (Fig. 1A). The F2L-induced HUVEC chemotaxis was
apparent at 1–20 lM (Fig. 1A). Another FPRL1 agonist (LL-
37) also stimulated HUVEC chemotaxis in a concentration-
dependent manner and showing maximal activity around
10 lM (Fig. 1B). Furthermore, chemotactic migration induced
by F2L or LL-37 was completely inhibited by PTX (Fig. 1C),
which highlights the importance of PTX-sensitive G-proteins
in chemotactic migration.
3.2. F2L-induced HUVEC chemotactic migration is mediated by
FPRL1
Since F2L has been reported to induce the chemotactic
migration of mouse neutrophils via FPR2 (mouse counterpart
of human FPRL1) [15], we tested whether F2L stimulates the
chemotactic migration of HUVECs via FPRL1, with the aid of
an FPRL1-selective antagonist (WRW4) [18]. The F2L-in-
duced HUVEC chemotaxis was completely inhibited by
WRW4 (Fig. 2). The LL-37-induced HUVEC chemotaxis
was also almost completely inhibited by WRW4 (Fig. 2). How-
ever, we found the S1P-induced HUVEC chemotaxis not to be
inhibited by WRW4, which suggests that F2L stimulates HU-
VEC chemotaxis via FPRL1.
3.3. F2L inhibits LL-37-induced endothelial cell proliferation
HUVECs are endothelial cells, which express functional
FPRL1 [14,22], whilst LL-37 (an agonist for FPRL1) has pre-
viously been reported to induce endothelial cell proliferation
[13,23]. We found that the stimulation of HUVECs with
5 lM of LL-37 elicited cell proliferation (Fig. 3). However,
F2L alone (20 lM) did not aﬀect HUVEC proliferation
(Fig. 3). We subsequently investigated the inﬂuence of F2L
on LL-37-induced endothelial cell proliferation. The stimula-
tion of HUVECs with F2L (20 lM) prior to the incubation
with LL-37 (5 lM) for 48 h, caused an almost complete inhibi-
tion of LL-37-induced cell proliferation, compared to cells
treated with LL-37 alone (Fig. 3). These results indicate that
F2L inhibits LL-37-induced endothelial cell proliferation. Pre-
vious reports have also indicated that S1P induces endothelial
cell proliferation [24–26]. However, S1P-induced HUVEC pro-
liferation was not inhibited by F2L, suggesting that F2L selec-
tively inhibits HUVEC proliferation through the inhibition of
FPRL1 (Fig. 3).
3.4. The stimulation of HUVECs with F2L inhibits angiogenesis
by LL-37
LL-37 has been reported to induce physiologic and patho-
logic angiogenesis in vivo [13,27]. In addition, FPRL1 has been
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Fig. 1. The eﬀect of F2L on the chemotactic migration in HUVECs. The HUVECs (1 · 106 cells/ml of serum free RPMI 1640 medium) were added
to the upper wells of a 96-well chemotaxis chamber and assessed for the migration across a membrane with an 8 lm pore size after incubation at
37 C for 4 h. Various concentrations of F2L (A) or LL-37 (B) were used for the chemotaxis assays. Next, the HUVECs were incubated in the
presence or absence of 100 ng/ml of PTX for 20 h. Following this, we added cultured HUVECs (1 · 106 cells/ml of serum free RPMI 1640 medium) to
the upper wells of a 96-well chemotaxis chamber, and calculated the migration across a membrane with an 8 lm pore size after incubation at 37 C
for 4 h. The number of cells which migrated across the membrane was determined by counting the cells in three HPF (400·). The data are expressed
as the means ± S.E. of three independent experiments which were performed in duplicate (A–C). *Statistical signiﬁcance was set at P < 0.05 against
the control (vehicle). #Number of statistically signiﬁcant values (P < 0.05) against the control (-PTX).
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LL-37 [13,23]. Hence, we attempted to determine whether F2L
alters tube formation in the LL-37-treated HUVECs. We ob-
served signiﬁcant tube formation when 5 lM LL-37 was ap-
plied during tube formation assays (Fig. 4). Moreover, F2L
alone had no eﬀect on tube formation (Fig. 4). However, the
addition of 20 lM of F2L, coupled with LL-37, dramatically
decreased LL-37-induced tube formation (Fig. 4). In addition,
S1P induced the tube formation in HUVECs; however, it was
not aﬀected by F2L (Fig. 4). These results suggest that F2L
acts upon FPRL1 to block LL-37-induced tube formation.4. Discussion
We found that F2L alone stimulated the chemotactic migra-
tion of HUVECs (Fig. 1). In addition, the F2L-induced HU-
VEC chemotaxis was completely inhibited by an FPRL1antagonist (WRW4) (Fig. 2). The results strongly suggest that
F2L stimulates HUVEC chemotaxis via FPRL1. The result
that the F2L-induced cell migration was completely inhibited
by PTX (Fig. 1C), supports our notion that F2L stimulates
HUVEC chemotaxis via FPRL1. Despite these facts, F2L
failed to stimulate cell proliferation and tube formation. More-
over, F2L inhibited signaling induced by the FPRL1 agonist
LL-37 (Figs. 3 and 4). In summary, these data strongly suggest
that F2L has a dual role as a partial agonist for FPRL1, as well
as an inhibitor for the FPRL1 agonist LL-37-induced signa-
lings in HUVECs.
According to previous reports, LL-37 which is made up of
an antimicrobial peptide, has multiple roles in innate immu-
nity, linking host defense and inﬂammation with angiogenesis
and arteriogenesis [13,23,28]. In this study, we demonstrated
that F2L has an inhibitory eﬀect on the LL-37-induced prolif-
eration of HUVECs (Fig. 3). We also showed that LL-37-in-
duced tube formation was completely inhibited by the
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Fig. 2. The eﬀect of the FPRL1 antagonist on the F2L-induced
HUVEC chemotaxis. HUVECs were incubated in the presence or
absence of 10 lMWRW4 for 15 min prior to the chemotaxis assay using
20 lM of F2L, 10 lM of LL-37, or 2 lM of S1P. The number of cells
that migrated across the membrane was determined by counting three
HPF (400·). Moreover, the data are expressed as the means ± S.E. of
three independent experiments which were performed in duplicate.
*Statistical signiﬁcance was set at (P < 0.05) against the control
(vehicle). #The number of statistically signiﬁcant values (P < 0.05)
against the control (DMSO treated).
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Fig. 3. The eﬀect of F2L on HUVEC proliferation as a function of
LL-37. The HUVECs were plated onto 24-well plates in triplicate,
followed by stimulation with LL-37 (5 lM), or S1P (100 nM) for 48 h
in the presence or absence of F2L (20 lM) pretreatment for 1 h. The
cell proliferation was determined by [3H]-thymidine incorporation
assays. The data are expressed as the means ± S.E. of three indepen-
dent experiments which were performed in duplicate. *The results
indicate a signiﬁcant diﬀerence at a P-value <0.05.
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Fig. 4. The eﬀect of F2L on the LL-37-induced tube formation in
HUVECs. The HUVECs were seeded onto 48-well plates and pre-
coated with Matrigel. Next, HUVECs was incubated with LL-37
(5 lM) or S1P (100 nM) in the presence or absence of F2L (20 lM).
After an 18 h incubation period, we assessed the tube formation by
obtaining photographs from an inverted phase contrast microscope
image (50·) (A). The bar graph indicates the total length of the tubes
formed by the HUVECs (B). The data are expressed as the
means ± S.E. of three independent experiments. *The results indicate
a signiﬁcant diﬀerence at a P-value <0.05.
276 S.Y. Lee et al. / FEBS Letters 582 (2008) 273–278addition of F2L (Fig. 4). These results suggest a new aspect for
the role of F2L in HUVECs as a negative modulator of cell
proliferation and angiogenesis. The molecular mechanism in-
volved in the LL-37-induced angiogenesis, FPRL1 was found
to mediate cellular responses to LL-37 [13]. Furthermore, in
a previous report, we clearly demonstrated that F2L directlybinds to FPRL1 and competitively inhibits the binding of
WKYMVm (an agonist for FPRL1) [16]. To sum up, F2L
may inhibit LL-37-induced cell proliferation and tube forma-
tion by acting on FPRL1 in HUVECs.
Originally, F2L was identiﬁed as a proteolytic fragment of
the heme-binding protein [14]. Furthermore, it is known that
apoptotic cells release chemotactic factors to attract phago-
cytes. F2L act as a chemoattractant for monocytes, and den-
dritic cells that would induce cellular responses against
apoptotic cells [14]. Interestingly, we also found that F2L in-
duced the chemotactic migration of endothelial cells, indicat-
S.Y. Lee et al. / FEBS Letters 582 (2008) 273–278 277ing a role of F2L in endothelial cell functioning. However, the
F2L inhibited cell proliferation and tube formation induced by
the activation of FPRL1 with LL-37 (an FPRL1 agonist)
(Figs. 3 and 4). Since HUVECs express FPRL1, the inhibition
of cell proliferation and tube formation by F2L, which is re-
leased from the heme-binding protein, must be mediated by
antagonizing FPRL1. Taken together, these ﬁndings suggest
a putative anti-inﬂammatory role for F2L, through its inhibi-
tion of FPRL1 activation in human endothelial cells for a
number of vascular inﬂammatory diseases associated with cell
death.
Several previous reports on chemokines have also demon-
strated that certain chemokines have dual roles as an agonist
for one chemokine receptor and as an antagonist for another
receptor [29,30]. For example, CCL26 (eotaxin) which is a nat-
ural agonist of CCR3, acts as an antagonist for CCR2 and
CCR5 [29,30]. CCL7 (MCP-3) is an agonist of CCR1,
CCR2, and CCR3, and has been reported to be a natural
antagonist at CCR5, thereby inhibiting the functional re-
sponses of CCR5 to other ligands [31]. In this study, we dem-
onstrated that F2L (an agonist for FPRL2) can act as a
negative regulator for FPRL1-mediated signaling. Based on
our studies, we suggest that multiple FPR family members
can also be diﬀerentially modulated by the F2L ligand.
Although the functional signiﬁcance of natural antagonism
in the FPR family is not fully understood, it may be important
for the eﬃcient regulation of FPR family-related responses.
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